Rockville-based Neuralstem reports higher 2Q loss

Neuralstem Inc., of Rockville, a biotherapeutic company developing products to treat central nervous system disorders with patented stem cell technology, reported a second-quarter net loss of $6.25 million, or 9 cents per share, compared to a net loss of $2.5 million, or 4 cents per share, in the prior-year period.

Leave a Reply

Your email address will not be published. Required fields are marked *